Medical technology conglomerate Abbott announced on Wednesday that it has secured Europe’s CE mark for its novel Libre Duo device, establishing the world’s first dual-analyte sensor engineered to continuously monitor both glucose and ketone levels simultaneously. The breakthrough diagnostic technology is structurally designed to optimize diabetes management by detecting escalating systemic ketone parameters. This metric serves as a critical early warning biomarker for diabetic ketoacidosis (DKA), a life-threatening clinical complication triggered by an acute deficit of insulin.
The primary technological parameters, commercial launch frameworks, and international regulatory timelines defining the system feature:
-
Product Portfolio and Indication Profiles: Abbott plans to execute the commercial rollout of the systems across selected European jurisdictions within this year, branded under two distinct configurations:
-
Libre Duo: Features a continuous 15-day operational wear time, indicated strictly for adult patient populations aged 18 and older.
-
Libre Duo 10 Day: Configured with a compressed 10-day functional lifespan, designed for pediatric and adult utilization spanning individuals aged two and older.
-
-
Clinical Workflow Optimization: The Libre Duo architecture allows users to continuously monitor dual metabolic signals, completely removing the clinical necessity for traditional finger-stick blood draws or urine test strips typically utilized to check ketone levels. Diabetologists heavily recommend routine ketone testing during periods of acute somatic illness, when the body naturally releases stress hormones that rapidly drive up blood sugar concentrations. Early pathognomonic symptoms of DKA, such as nausea or chronic fatigue, are frequently misdiagnosed as routine illnesses, dangerously delaying clinical recognition and targeted treatment intervention.
-
Digital Ecosystem Integration: Abbott noted that users will be empowered to share real-time glucose and ketone data streams seamlessly with familial caregivers and healthcare providers. Concurrently, the manufacturer is advancing technical collaborations with automated insulin pump developers to enable automated insulin delivery (AID) closed-loop systems to interface directly with Libre Duo hardware.
-
Divergent Regulatory Trajectories: Capturing the CE mark formally clears Abbott to initiate immediate commercial marketing operations across regulated European territories. Parallel to this European expansion, the dual-analyte system is undergoing active regulatory review by the U.S. Food and Drug Administration (FDA). Abbott’s executive leadership team, led by CEO Robert Ford, indicated to institutional investors that the company anticipates formal U.S. clearance in the second half of this year.
The regulatory clearance materializes as a significant milestone tracing back to 2022, when CEO Robert Ford first unveiled conceptual blueprints for multi-signal biowearables tracking glucose, ketones, and lactate at the Consumer Electronics Show. The authorization supplementary aligns with parallel cross-industry efforts by key global stakeholders, including the prominent non-profit Breakthrough T1D, to establish standardized clinical best practices for continuous ketone monitoring. In terms of market competition, chief rival Dexcom has acknowledged internal development tracks for dual-analyte sensing, though corporate leaders confirmed its continuous ketone programs remain positioned further out on the horizon. Dexcom intends to pivot its near-term corporate assets toward co-monitoring glucose and potassium to support patient cohorts navigating dual diabetes and chronic kidney disease pathologies.
Source: https://www.yahoo.com/news/